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Abstract
Background: The purpose of this study was to examine the effect of a 10-week exercise therapy
regimen on activities of daily living (ADL) and perceived health status in patients with Parkinson
disease.
Methods: Twenty-four Parkinson's disease patients entered into the study. Participants were
allocated into the experimental (n = 12) or control group (n = 12). ADL was assessed using the
Short Parkinson Evaluation Scale/Scale for Outcomes in Parkinson Disease (SPES/SCOPA) and
perceived health status was measured using the Parkinson's Disease Quality of Life (PDQL)
questionnaire. Patients in the experimental group received pharmacological therapy plus a 1-hour
exercise therapy session 4 times a week, while patients in the control group received
pharmacological therapy only. The Mann-Whitney U test was used for comparison.
Results: The mean age of participants was 59.8 (SD = 3.0) and 58.2 (SD = 3.4) years in the
experimental and control groups, respectively. The median Hoehn and Yahr stage was 3.0 for both
groups. There were no significant differences in all subscales and overall scores between two
groups at baseline. However, after the intervention, except for the emotional functioning (P =
0.27), there were significant differences between the two groups for Parkinson symptoms, systemic
symptoms, social functioning, and overall scores of the PDQL (all P values < 0.05), and the ADL (P
= 0.01) indicating that quality of life was improved in the experimental group.
Conclusion:  The findings from this small scale quasi-randomised trial showed that exercise
therapy was effective in improving activities of daily living and perceived health status in patients
with Parkinson's disease. Indeed, exercise therapy could be offered to patients with Parkinson
disease, considering that it is low in cost and usually has no negative side effects.
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Background
Parkinson disease is a complex neurodegenerative condi-
tion with both motor and non-motor symptoms [1]. Due
to a progressive loss of substantia nigra neurons, which
produce dopamine, neurotransmitter imbalances occur in
the basal ganglia [2]. If around 80% of neurons have been
lost, Parkinson disease become evident and patients begin
to experience a vide variety of difficulties [3].
The most clinical features of Parkinson disease are motor
symptoms including tremor at rest, rigidity, and bradyki-
nesia [4]. These impairments cause decline in functional
status so that the patients cannot cope with tasks such as
walking, rising from a chair, moving in bed, eating, or
putting on shoes [5]. Limitation in functional status and
activities of daily living often results in a loss of independ-
ence and decline in quality of life. It has been shown that
patients with Parkinson disease, compared to the general
population, have lower mobility and physical functioning
[5,6]. Therefore, it can be expected that, as a result of the
combined Parkinson disease impairment and inactivity,
patients with Parkinson disease could enter into a down-
ward spiral of immobility; which causes progressively
increasing deficits in muscle strength, and quality of life
[5].
Management of patients with Parkinson disease should be
a multidisciplinary approach, which includes a coordina-
tion of pharmacological and non-pharmacological treat-
ment [1,7]. It has been suggested that physical therapy as
an effective non-pharmacological treatment has positive
effects on mobility and activities of daily living in individ-
uals with Parkinson disease [8]. Physical therapy in con-
junction with routine medication for patients with
Parkinson disease could break the downward spiral of
immobility. However, only few randomised trials have
investigated the effects of physical therapy on the quality
of life of patients with Parkinson disease [9-14]. Although
a recent meta-analysis of fourteen randomised trials of the
effectiveness of exercise interventions supported that exer-
cise was beneficial in improving physical functioning and
health-related quality of life in patients with Parkinson
disease, it indicated that questions about optimal content
of exercise interventions (dosing and components)
remain to be answered [15].
The aim of this small scale study was to investigate
whether an exercise therapy regimen is effective in
improving activities of daily living and quality of life in
patients with Parkinson disease in order to add this non-
pharmacological intervention as a routine regimen for
suitable candidate among our patients in Iran.
Methods
Ethics
The ethics committee of Razi University (Kermanshah,
Iran) approved the study. All patients gave their consent.
Participants
A consecutive sample of 24 male patients with an idio-
pathic Parkinson disease diagnosed by a neurologist, with
the following criteria were entered into the study: age ≤ 65
years, stage 2 to 3 of the Hoehn and Yahr scales [16], no
cardiovascular, orthopaedic, or other neurological dis-
ease, no cognitive impairment (MMSE score >24; [17]),
and had not received exercise therapy within the 6 months
prior to the study.
Procedure
Before the beginning of the intervention, every other
patient was allocated into the control or experimental
group (12 participants in each group) by a nurse who was
not connected to the study. She was responsible to explain
the study and randomly allocate patients to the study
arms and ask their permission for the trial. During the
study period, all patients in both groups continued their
routine pharmacological treatment. The pharmacological
treatment for all patients was the same and remained
unchanged during the study period. Patients received Sin-
met (Levodopa-c 100 mg/10 mg, twice per day), Artan
(Trihexyphinidyl, 1 mg per day), Selegiline (5 mg twice
per ay) and Amantadin (100 mg twice per day) as their
medication. Both groups completed activities of daily liv-
ing and quality of life measures twice: once before inter-
vention and once one month after exercise sessions and
group meetings. A physiotherapist who was blind to the
group allocation and was not connected to the study
supervised the procedure and helped to collect the data.
There were no withdrawals.
Intervention
Exercise therapy consisted of 10 weeks in which partici-
pants in the experimental group, in conjunction with their
pharmacological therapy, came to the clinic 4 days a week
about 1 hour after taking their PD medications. Each exer-
cise therapy session lasted for 1 hour, beginning with
about 10 minutes warm-up (walking, moderate stretching
and breathing training). Main body of the session lasted
40 to 50 minutes and included three parts: postural,
stretching, and strengthening exercises recommended for
PD patients by the Parkinson Society Canada. The reason
for choosing this programme was due to its availability,
simplicity, and instructive pictures. For each part there
were several practical training and movements such as
standing, sitting, waking up, a range of movement for
joints and muscles by holding positions and relaxing, and
strengthening body muscles exercises [see http://
www.parkinson.ca]. Each session was ended with 5 min-Trials 2009, 10:67 http://www.trialsjournal.com/content/10/1/67
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utes of relaxation and breathing training. One of the
authors led the patients through the same controlled
standardized series of exercises at each session. Partici-
pants in the control group received only their pharmaco-
logical therapy. However, they also gathered together 4
times a week to receive general lectures on health topics
and PD, attention and the feeling of being in a group. The
authors also controlled these sessions. There were 6 partic-
ipants during each session of the exercise and control
group interventions.
Measures
The activities of daily living (ADL) subscale of the Short
Parkinson Evaluation Scale/Scales for Outcomes in Par-
kinson disease (SPES/SCOPA) was used to assess activities
of daily living of the participants. Marinus et al. developed
the scale and they reported that it is a reliable and valid
measure and can be used both in research settings and
clinical practices [18]. The ADL subscale of the SPES/
SCOPA consists of 7 questions about speech, feeding,
dressing, hygiene, changing position, walking, and hand
writing with 4 response categories (from normal = 0 to
severe = 3). This gives scores ranging from 0 to 21 with
higher scores indicating a poorer condition.
Perceived health status was measured using the Parkinson
Disease Quality of Life (PDQL) questionnaire. The PDQL
is a self-administered measure which contains 4 subscales:
Parkinson symptoms (PS- 14 items), systemic symptoms
(SS- 7 items), social functioning (SF- 7 items), and emo-
tional functioning (EF- 9 items); and an overall score can
be derived, with a higher score indicating better perceived
quality of life [19]. Each item is rated on a 5-point scale.
This gives scores ranging from 0 to 70, 0 to 35, 0 to 35, 0
to 45, and 0 to 185 for PS, SS, SF, EM and total scores
respectively.
Both instruments were translated from English to Persian
(the Iranian language) using forward-backward transla-
tion method [20]. Internal consistency for the ADL and
the PDQL questionnaires were measured and showed sat-
isfactory results (Cronbach's α equal or greater than 0.70).
Statistical analysis
The Mann-Whitney U test was used to compare the
patients' characteristics, activities of daily living, and qual-
ity of life scores between the two groups at baseline (pre-
test) and at follow-up (post-test). Also similar analysis
was performed to compare changes in scores (post-test
minus pre-test scores) between the experimental and the
control groups. All statistical analyses were performed
using SPSS for windows, version 15.0 and statistical sig-
nificance was set at p < 0.05.
Results
In all 24 male patients were entered into the study. During
patient allocation there were 8 female and 4 male patients
that screened for eligibility but failed. None of the patients
started the study and were allocated to experimental or
control groups dropped out. The mean age of participants
was 59.8 (SD = 3.0) and 58.2 (SD = 3.4) years in the exper-
imental and control groups, respectively. The median
Hoehn and Yahr stage was 3.0 for both groups. There were
no significant differences between the two groups with
regard to their demographic and clinical status (Table 1).
The main findings of the study are summarized in Tables
2 and 3. There were no significant differences in all sub-
scales and overall scores of the PDQL as well as the ADL
score between the two groups at baseline. However, after
treatment, except for the emotional functioning, there
were significant differences between the two groups indi-
Table 1: The characteristics of experimental and control groups
Experimental group (n = 12) Control group (n = 12)
Mean (SD) Mean (SD) P
Age (year) 59.8 (3.0) 58.2 (3.4) 0.24
Range 54–65 52–64
Disease duration (year) 4.8 (1.1) 4.4 (1.2) 0.39
Stage (Hoehn and Yahr scale) 2.8 (0.3) 2.7 (0.4) 0.58
Median 3.0 3.0
1st quartile 3.0 2.2
Range 2–3 2–3Trials 2009, 10:67 http://www.trialsjournal.com/content/10/1/67
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Table 2: Comparison of pre-test PDQL and ADL scores between experimental and control groups
Experimental group (n = 12) Control group (n = 12)
Mean (SD) Median (range) Mean (SD) Median (range) P
PDQL score*
PS 41.2 (9.8) 41.0 (24–60) 40.0 (9.7) 39.5 (25–58) 0.75
SS 17.8 (3.7) 18.0 (10–24) 17.6 (3.2) 17.5 (10–22) 0.83
EF 23.3 (6.4) 23.0 (12–40) 23.3 (4.1) 24.0 (14–30) 0.62
SF 18.1 (2.7) 18.5 (12–22) 17.6 (2.8) 18.5 (12–21) 0.72
Total score 100.7 (22.1) 101.0 (58–149) 98.6 (17.4) 103.0 (61–122) 0.88
ADL score**
Activities of daily living score 7.0 (1.3) 7.0 (5–9) 6.4 (1.8) 7.0 (4–9) 0.44
Abbreviations. PDQL: the Parkinson Disease Quality of Life questionnaire; ADL: Activities of daily living; PS: Parkinson symptoms; SS: Systemic 
symptoms; EF: Emotional functioning; SF: Social functioning;
* Higher scores indicate better conditions.
** Higher score indicates a poorer condition.
Table 3: Comparison of post-test PDQL and ADL scores between experimental and control groups
Experimental group (n = 12) Control group (n = 12)
Mean (SD) Median (range) Mean (SD) Median (range) P
PDQL score*
PS 48.3 (9.8) 51.0 (24–62) 38.7 (8.4) 39.5 (27–54) 0.01
SS 21.3 (4.3) 22.0 (10–26) 16.5 (3.0) 17.5 (10–20) 0.001
EF 21.1 (3.4) 22.0 (12–25) 21.5 (3.2) 22.5 (14–25) 0.54
SF 21.0 (3.3) 22.0 (12–25) 17.9 (3.2) 19.0 (12–22) 0.007
Total score 115.4 (22.3) 120.5 (56–140) 95.6 (15.6) 100.0 (65–116) 0.006
ADL score**
Activities of daily living score 5.1 (0.7) 5.0 (4–6) 6.7 (1.5) 7.0 (4–9) 0.008
Abbreviations. PDQL: the Parkinson Disease Quality of Life questionnaire; ADL: Activities of daily living; PS: Parkinson symptoms; SS: Systemic 
symptoms; EF: Emotional functioning; SF: Social functioning;
* Higher scores indicate better conditions.
** Higher score indicates a poorer condition.Trials 2009, 10:67 http://www.trialsjournal.com/content/10/1/67
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cating that quality of life and activities of daily living were
improved in the experimental group.
Finally the mean change scores between the experimental
and control groups were compared. There were significant
differences in score changes for all measures between
experimental and the control groups (from pre to post-
test) except for emotional functioning. The results are
shown in Table 4.
Discussion
As suggested Parkinson disease is in an active state of evo-
lution [21]. The aim of this study was to determine
whether exercise therapy would enhance activities of daily
living and quality of life in patients with Parkinson dis-
ease. The results indicated that a 10-week exercise therapy
regimen (a 1-hour session four times per week), in con-
junction with the pharmacological therapy, could have
positive effects on ADL and QOL in patients with Parkin-
son disease. These results are in accordance with other
research findings where many investigators showed that
for treatment of patients with Parkinson disease, combi-
nation of pharmacological therapy and exercise is more
effective than using only the pharmacological therapy.
However, one should note that different rehabilitation
programmes might show different effects. For instance,
studies have shown that physical training could improve
the QOL and some ADL components such as standing
from chair, turning in bed, and getting in and out of bed
[9], or an 8-week Pole-Striding exercise could increase per-
ceived functional independence and QOL [10], or a 36-
session of aerobic conditioning and strengthening train-
ing could significantly improve QOL [11]. In contrast,
Burini et al. observed no effects for 40 aerobic and Qigong
training sessions on the quality of life of Parkinson dis-
ease participants [12]. Keus et al. showed that physical
therapy in conjunction with pharmacological treatment
improved quality of life, but suggested that physical ther-
apy is unlikely to influence the disease itself. However,
they argued that physical therapy could improve daily
functioning by teaching and training patients in the use of
movement strategies [22]. In addition, a recent review of
the literature indicated that there was insufficient evi-
dence to support that exercise would reduce falls or
depression in patients with Parkinson disease [15].
The study findings indicated a positive effect of exercise
therapy regimen on social functioning in patients. In the
PDQL questionnaire, social functioning includes abilities
to perform social activities like hobbies, leisure activities,
transport, and go on holiday [19]. These activities are
linked to motor ability. Thus, the observed improvement
might be explained by the fact that exercise therapy
improved motor function that in turn improved social
functioning in patients.
Table 4: Comparison of mean changes between experimental and control groups
Experimental group
(n = 12)
Control group
(n = 12)
Mean change (SD)
(post-test minus pre-test)
Mean change (SD)
(post-test minus pre-test)
P
PDQL*
Parkinson symptoms 7.1 (4.9) -1.3 (3.7) 0.001
Systemic symptoms 3.5 (2.3) -1.1 (3.9) 0.001
Emotional functioning -2.3 (5.2) -1.8 (1.5) 0.27
Social functioning 3.0 (2.6) 0.3 (1.7) 0.004
Total PDQL 14.7 (11.3) -3.0 (4.5) 0.001
ADL**
Activities of daily living score -1.9 (1.2) 0.3 (2.4) 0.01
* Negative values show deterioration.
** Negative value shows improvement.Trials 2009, 10:67 http://www.trialsjournal.com/content/10/1/67
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Emotional functioning was decreased in both groups.
However, the deterioration was greater in the intervention
group. This subscale is characterized with some feelings
such as insecure feeling due to physical limitation, feeling
embarrassed about disease, being afraid of progression of
illness, depression, and concentration difficulties [19].
Decrease in scores for both groups might be attributed to
patients' knowledge of disease progression. Nevertheless,
as suggested the results highlight the need for providing
psychological interventions in these patients in order to
enhance QOL [23]. Studies have shown that even mood
symptoms could be regarded as one of the main determi-
nants of poor quality of life in patients with Parkinson
disease [24].
The positive effects of physical training interventions on
improvement of motor performance related to changes in
position, which affects ADL, could be explained by the
fact that physical activities could help to break the cycle of
immobility [9]. In addition, stretching exercises could be
helpful for patients with PD by maintaining and improv-
ing the range of motion, and therefore keeping muscle
flexibility and strength [25]. Also stretching exercises
could help PD patients to improve their posture due to
enhancement of trunk mobility and activating of the
extensor muscles [26]. Scandalis et al. reported that
patients with PD, like other elderly people, could increase
their muscle strength through a resistance-training pro-
gram, and as a result, can enhance their posture, stride
length, and gait speed [27].
We used a well-known questionnaire (the PDQL) to
measure perceived health status in patients with PD. Stud-
ies of patients with Parkinson disease have shown that the
psychometric properties of the questionnaire were desira-
ble [28]. It is argued that using generic measures, such as
the Short Form Health Survey (SF-36), to assess quality of
life in patients with Parkinson disease might end with
misleading results. For instance a study showed that the
two SF-36 summary measures were not found to be valid
indicators of physical and mental health in patients with
Parkinson disease [29]. Indeed future studies of quality of
life in patients with Parkinson disease should define what
constitute health-related quality of life in PD patients at
first place, and secondly employ sound measures to avoid
misleading findings [30]. However, as suggested by Hagell
and Nygren even in using such measures (e.g. the 39-item
Parkinson's Disease Questionnaire-PDQ-39) endpoints
should be interpreted cautiously particularly small but
clinically important effects among patients with severe
problems [31].
The very small sample size could be regarded as the main
limitation of this study. In addition, because none of the
female patients met the study inclusion criteria, women
patients were not included in this study. This fact limits
the external validity (generalizability) of the results. Also
the short duration of the study and the fact that there was
no follow-up to evaluate whether the differences in two
groups maintained is another limitation. Finally, since
patients were not blind there might be an overestimation
of the intervention effect adherent to the study results. In
fact, the study design was quasi-randomisation and thus
failed to maintain adequate allocation concealment
[32,33]
Conclusion
Exercise therapy in conjunction with pharmacological
therapy was effective in improving activities of daily living
and perceived health status in patients with Parkinson dis-
ease. Indeed, exercise therapy could be offered to patients
with Parkinson disease, considering that it is low in cost
and usually has no negative side effects.
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